(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
30 July 2009 (30.07.2009)

PCT

(10) International Publication Number
WO 2009/093032 A1

(51) International Patent Classification:
C07D 401/10 (2006.01) *C07D 491/10* (2006.01)
C07D 401/14 (2006.01) *A61K 31/502* (2006.01)
C07D 405/14 (2006.01) *A61K 31/5025* (2006.01)
C07D 487/04 (2006.01) *A61P 35/00* (2006.01)

(21) International Application Number:
PCT/GB2009/000181

(22) International Filing Date: 23 January 2009 (23.01.2009)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
61/022,900 23 January 2008 (23.01.2008) US
61/142,413 5 January 2009 (05.01.2009) US

(71) Applicant *(for all designated States except US)*: **ASTRAZENECA AB** [SE/SE]; SE-151 85 Sodertalje (SE).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **MENEAR, Keith, Allan** [GB/GB]; Kudos Pharmaceuticals Limited 410, Cambridge Science Park, Milton Road, Cambridge Cambridgeshire CB4 0PE (GB). **JAVAID, Muhammad, Hashim** [GB/GB]; Kudos Pharmaceuticals Limited, 410 Cambridge Science Park, Milton Road, Cambridge Cambridgeshire CB4 0PE (GB). **GOMEZ, Sylvie** [FR/GB]; Kudos Pharmaceuticals Limited, 410 Cambridge Science Park, Milton Road, Cambridge Cambridgeshire CB4 0PE (GB). **HUMMERSONE, Marc, Geoffrey** [GB/GB]; Kudos Pharmaceuticals Limited, 410 Cambridge Science Park, Milton Road, Cambridge Cambridgeshire CB4 0PE (GB). **LENCE, Carlos, Fenandez** [ES/GB]; Kudos Pharmaceuticals Limited, 427 Cambridge Science Park, Milton Road, Cambridge Cambridgeshire CB4 0WE (GB). **MARTIN, Niall, Morrison, Barr** [GB/GB]; Kudos Pharmaceuticals Limited 410, Cambridge Science Park, Milton Road, Cambridge Cambridgeshire CB4 0PE (GB). **RUDGE, David, Alan** [GB/GB]; AstraZeneca PLC, Mereside, Alderley Park, Macclesfield Cheshire SK10 4TG (GB). **ROBERTS, Craig, Anthony** [GB/GB]; AstraZeneca PLC, Mereside, Alderley Park, Macclesfield, Cheshire SK10 4TG (GB). **BLADES, Kevin** [GB/GB]; AstraZeneca PLC, Mereside, Alderely Park, Macclesfield Cheshire SK10 4TG (GB).


(74) Agent: **WATSON, Robert**; Mewburn Ellis LLP, 33 Gutter Lane, London, Greater London EC2V 8AS (GB).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ,

[Continued on next page]

(54) Title: PHTHALAZINONE DERIVATIVES



(I)

(57) Abstract: A compound of the formula (I): wherein: A and B together represent an optionally substituted, fused aromatic ring; X and Y are selected from CH and CH, CF and CH, CH and CF and N and CH respectively; R^c is selected from H, C_{1-4} alkyl; and R^1 is selected from C_{1-7} alkyl, C_{3-20} heterocydyl and C_{5-20} aryl, which groups are optionally substituted; or R^c and R^1 together with the carbon and oxygen atoms to which they are attached form a spiro-C_{5-7} oxygen-containing heterocyclic group, which is optionally substituted or fused to a C_{5-7} aromatic ring. These compounds are useful in the preparation of a medicament for inhibiting the activity of PARP for the treatment of : vascular disease; septic shock;ischaemic injury;neurotoxicity;haemorraghic shock;viral infection; or for use as an adjunct in cancer therapy or for potentiating tumour cells for treatment with ionizing radiation or chemotherapeutic agents.

WO 2009/093032 A1

CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report*